BeOne's Beat-and-Raise: Chemo-Free MCL and Real-World Survival Data Turn BRUKINSA into a Growth Story About Duration
Q2 2026 delivered 30% revenue growth, raised guidance, and a pipeline at a registrational tipping point—anchored by real-world evidence that’s changing internal planning assumptions.
ONC · Earnings Call · 2026-08-05
BeOne Medicines is no longer just the best-selling BTK inhibitor story; Q2 2026 marked the moment the company's long-term growth algorithm shifted from share-taking to duration and from pipeline promises to registrational inflection. Total revenue reached $1.7B (up 30% y/y), GAAP EPS more than doubled to $2.05, and management raised full-year guidance by $300M in revenue and $250M in operating income. The stock's 90-day move of +21% is a vote of confidence, but the deeper signal is in the company's own framing: the BRUKINSA franchise is now growing on the strength of real-world evidence and a landmark PFS advantage that is finally showing up in patient acquisition and duration of therapy.
The Duration Advantage Becomes a Growth Engine
Aaron Rosenberg, CFO, was explicit: “As a result of data such as this, we have updated our internal planning assumptions to reflect longer duration of therapy.” — Aaron Rosenberg, CFO or Head of Finance · 2026-08-05 This is a fundamental change in how Wall Street should model BRUKINSA. New patient starts are at an all-time high, and the company now has data from more than 10,500 Medicare patients showing a 24% and 36% reduction in risk of death vs acalabrutinib and ibrutinib. When combined with the durability advantage seen in the SEQUOIA and ALPINE trials, the franchise is no longer just winning share—it is extending the time patients stay on therapy, which is a direct driver of revenue.Total revenue reached $1.7B, with BRUKINSA contributing $1.2B globally—a 31% y/y increase.
The durability advantage that we're seeing in the clinical data for foundational BRUKINSA is increasingly being reinforced in the real world. And it's both consistent, and it's compelling.
MANGROVE and the Chemo-Free Future in MCL
The other pivotal development is MANGROVE, the Phase III study in frontline mantle cell lymphoma. The company's BCL-2 inhibitor program—BEQALZI—received FDA approval, but MANGROVE is the bigger prize: a chemo-free regimen (zanubrutinib + rituximab) that beat chemotherapy with a hazard ratio of 0.57. Amit Agarwal captured the physician response: “When we shared these results with physicians, KOLs, experts who treat MCL, they're really excited about this data.” — Amit Agarwal, Executive, likely Head of Clinical Development or similar · 2026-08-05 This is not just another indication; it opens a patient population that was previously treated with chemotherapy and provides a differentiated positioning against competitors like the ECHO regimen.
Solid Tumor Pipeline Hits Proof-of-Concept
Beyond hematology, the solid tumor franchise is reaching a tipping point. Five programs now have clinical proof of concept and are advancing to registrational trials. Lai Wang highlighted the speed: “Our CDK4 inhibitor has begun Phase III development in breast cancer. Our GPC3 4-1BB bispecific recently completed enrollment...” — Wang Lai, Executive, likely Head of Research or similar · 2026-08-05 The PRMT5 inhibitor and CEA ADC are heading toward Phase III, while the B7-H4 ADC is targeting ovarian cancer with a manageable safety profile.
Financial and Competitive Positioning
The guidance raise reflects confidence in this dual-engine model. Gross margin came in just under 90%, and free cash flow doubled to $435M in the quarter. Even after heavy R&D investment, the company is generating operating leverage. Gross margin expanded to just under 90% as mix and productivity benefits flowed through. On the competitive front, the company is aggressively defending its position against Acala+ven and pirto. Lai Wang's prior-year comment still resonates: “any new continuous BTKi needs to demonstrate superiority over BRUKINSA, not ibrutinib.” — Wang Lai, Chief Scientific Officer or Head of R&D (inferred from R&D discussion and portfolio update) · 2025-08-06 That stance is now backed by a head-to-head Phase III against pirto for the degrader. What changed at BeOne Medicines is not a single beat but the crystallization of a two-part thesis: BRUKINSA's duration advantage is now monetized, and the pipeline is moving from proof-of-concept to pivotal trials across multiple tumor types. The combination of real-world survival data, MANGROVE's chemo-free win, and a registrational wave makes this quarter a genuine inflection point.